Form 4: Beta Bionics CPO Sells Shares Under 10b5-1 Plan

Beta Bionics' Chief Product Officer, Mike Mensinger, sold 7,800 shares of common stock on January 2, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• Mike Mensinger, the Chief Product Officer of Beta Bionics, Inc. (BBNX), reported the sale of common stock.
• The transactions occurred on January 2, 2026.
• A total of 7,200 shares were sold at a weighted average price of $29.56 per share, with prices ranging from $29.05 to $30.02.
• An additional 600 shares were sold at a weighted average price of $30.1969 per share, with prices ranging from $30.10 to $30.52.
• These sales were executed pursuant to a Rule 10b5-1 Plan adopted on September 8, 2025.
• Following these transactions, Mr. Mensinger beneficially owns 82,952 shares of Beta Bionics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the reported transactions are sales of common stock by an insider, but they were conducted under a pre-arranged Rule 10b5-1 plan, which typically indicates a scheduled divestment rather than a reaction to new company-specific information.

Negatives

• An insider, the Chief Product Officer, sold a total of 7,800 shares of common stock.

Future Outlook

NA

Industry Context

This filing reports a routine insider stock transaction and does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders may observe a minor impact on sentiment due to insider selling, although the pre-arranged nature of the 10b5-1 plan mitigates concerns about management's immediate outlook on the company's prospects.

Key Dates

Recommendation

The reported insider sales were executed under a Rule 10b5-1 plan, which is a pre-scheduled trading arrangement. Such transactions are generally not indicative of a change in management's view on the company's future performance and therefore do not warrant a change in investment recommendation based solely on this filing. Investors should consider broader company fundamentals and market conditions.

Keywords

Beta Bionics, BBNX, Insider Transaction, Form 4, Stock Sale, 10b5-1 Plan, Mike Mensinger, Chief Product Officer